178.85
price up icon0.70%   +1.24
 
loading
Resmed Inc. stock is currently priced at $178.85, with a 24-hour trading volume of 1.28M. It has seen a +0.70% increased in the last 24 hours and a -7.34% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $177.9 pivot point. If it approaches the $179.5 resistance level, significant changes may occur.

Resmed Inc. Stock (RMD) Financials Data

Resmed Inc. (RMD) Revenue 2024

RMD reported a revenue (TTM) of $4.50 billion for the quarter ending December 31, 2023, a +19.69% rise year-over-year.
loading

Resmed Inc. (RMD) Net Income 2024

RMD net income (TTM) was $890.39 million for the quarter ending December 31, 2023, a +10.00% increase year-over-year.
loading

Resmed Inc. (RMD) Cash Flow 2024

RMD recorded a free cash flow (TTM) of $943.73 million for the quarter ending December 31, 2023, a +325.82% increase year-over-year.
loading

Resmed Inc. (RMD) Earnings per Share 2024

RMD earnings per share (TTM) was $6.05 for the quarter ending December 31, 2023, a +9.80% growth year-over-year.
loading

Resmed Inc. Stock (RMD) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Rider Michael J
Global General Counsel
Mar 04 '24
Sale
180.00
81
14,580
6,607
Rider Michael J
Global General Counsel
Mar 01 '24
Sale
173.25
200
34,650
6,688
FARRELL PETER C
Director
Feb 22 '24
Sale
182.66
10,935
1,997,434
157,404
Sandercock Brett
Chief Financial Officer
Nov 27 '23
Sale
152.62
3,000
457,860
92,962
Farrell Michael J.
Chief Executive Officer
Nov 15 '23
Option Exercise
57.76
5,678
327,961
446,664
Farrell Michael J.
Chief Executive Officer
Nov 15 '23
Sale
152.04
5,678
863,281
440,986
Rider Michael J
Global General Counsel
Nov 01 '23
Sale
143.42
25
3,585
7,358
Farrell Michael J.
Chief Executive Officer
Oct 16 '23
Option Exercise
57.76
5,675
327,788
455,035
Farrell Michael J.
Chief Executive Officer
Oct 16 '23
Sale
140.70
5,675
798,464
449,360
Rider Michael J
Global General Counsel
Oct 02 '23
Sale
145.92
25
3,648
7,383
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; data communications and control products, such as AirView Diagnostics, EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules; U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; and myAir, a patient engagement application that provides sleep data and a daily score based on their previous night's data, as well as offers business management software and services to medical equipment and home health providers. It markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
medical_instruments_supplies WST
$372.04
price down icon 1.40%
medical_instruments_supplies BAX
$39.47
price down icon 0.45%
medical_instruments_supplies COO
$90.42
price up icon 0.01%
$75.38
price up icon 0.37%
medical_instruments_supplies ALC
$79.55
price up icon 1.38%
Cap:     |  Volume (24h):